Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

格隆汇8月6日丨信利国际(00732.HK)宣布，集团于2025年7月未经审核综合营业净额约为14.68亿港元， 较2024年7月未经审核综合营业净额约15.18亿港元减少约3.3%。 集团截至2025年7月31日止七个月未经审核累计综合营业净额约为95.66亿港元，较截至2024年7月31日 止七个月累计综合营业净额约101.03亿港元减少约5.3%。 ...

Core Viewpoint - The company reported a decrease in unaudited consolidated operating revenue for July 2025 compared to July 2024, indicating a downward trend in financial performance [1] Financial Performance Summary - The unaudited consolidated operating revenue for July 2025 is approximately HKD 1.468 billion, a decrease of about 3.3% from approximately HKD 1.518 billion in July 2024 [1] - For the seven months ending July 31, 2025, the unaudited cumulative consolidated operating revenue is approximately HKD 9.566 billion, which represents a decrease of about 5.3% from approximately HKD 10.103 billion for the same period ending July 31, 2024 [1]

Core Viewpoint - The company, Xinyi International (00732), reported a decrease in its unaudited consolidated operating revenue for July 2025 compared to July 2024, indicating a downward trend in financial performance [1]. Financial Performance Summary - The unaudited consolidated operating revenue for July 2025 is approximately HKD 1.468 billion, a decrease of about 3.3% from the unaudited consolidated operating revenue of approximately HKD 1.518 billion for July 2024 [1]. - For the seven months ending July 31, 2025, the unaudited cumulative consolidated operating revenue is approximately HKD 9.566 billion, which represents a decrease of about 5.3% compared to the cumulative consolidated operating revenue of approximately HKD 10.103 billion for the same period in 2024 [1].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 致：香港交易及結算所有限公司 | | | --- | --- | | 公司名稱: | 信利國際有限公司 | | 呈交日期: | 2025年8月4日 | | I. 法定/註冊股本變動 | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00732 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 HKD | | 0.02 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 HKD | | 0.02 | HKD | | 100,000,000 | 本月底法定/註冊股本總額： H ...

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，7月25日有17家香港上市公司进行了股份回购，合计回购985.07万股，回购 金额2306.22万港元。 百胜中国回购数量1.67万股，回购金额626.79万港元，回购最高价为382.800港元，最低价为373.600港 元，年内累计回购金额9.81亿港元；华检医疗回购数量141.40万股，回购金额507.63万港元，回购最高 价为3.590港元，年内累计回购金额1442.59万港元；蒙牛乳业回购数量20.00万股，回购金额343.33万港 元，回购最高价为17.280港元，最低价为17.020港元，年内累计回购金额2.45亿港元。 7月25日港股公司回购一览 | | | | | | | 年内累计 | | --- | --- | --- | --- | --- | --- | --- | | 代码 | 简称 | 回购股数 | 回购金额 | 回购最高价 | 回购最低价 | 回购金额 | | | | （万股） | （万港元） | （港元） | （港元） | | | | | | | | | （万港元） | | 09987 | 百 ...

Group 1 - The article reports on share buybacks conducted by various companies on July 25, 2025, with Yum China (09987) having the largest buyback amount of 6.2679 million yuan for 16,700 shares [1][2] - The total number of shares repurchased by Yum China in the year reached 3.2541 million, accounting for 0.870% of its total share capital [2] - Other notable companies involved in buybacks include Huajian Medical (01931) with 1.414 million shares repurchased for 5.0763 million yuan, and Mengniu Dairy (02319) with 200,000 shares for 3.4333 million yuan [2] Group 2 - The buyback activities reflect a strategic move by companies to enhance shareholder value and signal confidence in their financial health [1] - The buyback amounts and share counts for other companies include Xinyi International (00732) with 2.644 million shares for 3.2257 million yuan, and Beike-W (02423) with 462,600 shares for 3 million yuan [2] - The data indicates a diverse range of companies participating in buybacks, suggesting a broader trend in the market towards returning capital to shareholders [1][2]

Group 1 - On July 24, 17 Hong Kong-listed companies conducted share buybacks, totaling 17.15 million shares and an amount of 16.89 million HKD [1][2] - China Eastern Airlines repurchased 1.5 million shares for 4.44 million HKD, with a highest price of 2.980 HKD and a lowest price of 2.920 HKD, accumulating a total buyback amount of 606 million HKD for the year [1][2] - Mengniu Dairy repurchased 200,000 shares for 3.45 million HKD, with a highest price of 17.300 HKD and a lowest price of 17.240 HKD, accumulating a total buyback amount of 242 million HKD for the year [1][2] Group 2 - IGG repurchased 560,000 shares for 2.40 million HKD, with a highest price of 4.310 HKD and a lowest price of 4.260 HKD, accumulating a total buyback amount of 56.65 million HKD for the year [1][2] - The highest buyback amount on July 24 was from China Eastern Airlines at 4.44 million HKD, followed by Mengniu Dairy at 3.45 million HKD [1][2] - The largest number of shares repurchased on July 24 was by Ying Group, with a buyback of 5.5 million shares, followed by China Electric Power and Shoujia Technology [1][2]

Summary of Key Points Core Viewpoint - On July 23, 21 Hong Kong-listed companies conducted share buybacks, totaling 20.97 million shares and an aggregate amount of HKD 44.00 million [1][2]. Group 1: Buyback Details - VITASOY INT'L repurchased 1.402 million shares for HKD 12.98 million, with a highest price of HKD 9.260 and a lowest price of HKD 9.230, accumulating HKD 151.00 million in buybacks for the year [1][2]. - China Eastern Airlines repurchased 2.50 million shares for HKD 7.32 million, with a highest price of HKD 2.970 and a lowest price of HKD 2.900, totaling HKD 601.30 million in buybacks for the year [1][2]. - China Feihe repurchased 1.00 million shares for HKD 4.70 million, with a highest price of HKD 4.700, accumulating HKD 93.00 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on July 23 was from VITASOY INT'L at HKD 12.98 million, followed by China Eastern Airlines at HKD 7.32 million [1][2]. - In terms of share quantity, the most shares repurchased were by Shoujia Technology at 7.40 million shares, followed by China Eastern Airlines at 2.50 million shares [1][2].

以金额进行统计，7月21日回购金额最多的是中国东方航空股份，回购金额为851.94万港元；其次是蒙 牛乳业，回购金额为342.07万港元；回购金额居前的还有IGG、名创优品等。回购数量上看，7月21日 回购股数最多的是嬴集团，当日回购量为400.00万股；其次是中电光谷、中国东方航空股份等，回购数 量分别为400.00万股、294.40万股。 证券时报·数据宝统计显示，7月21日有18家香港上市公司进行了股份回购，合计回购1367.05万股，回购 金额2125.31万港元。 值得关注的是，本次回购851.94万港元的中国东方航空股份，年内则进行多次回购，合计回购金额为 5.84亿港元。（数据宝） 7月21日港股公司回购一览 | 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 00670 | 中国东方航 空股份 | 294.40 | 851.94 | 2.910 | 2.850 | ...